Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Songgang Yi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Scientific Reports|February 23, 2016
A microRNA-mediated decrease in eukaryotic initiation factor 2α promotes cell survival during PS-341 treatmentLili Jiang, Dan Zang, Songgang Yi, et al.
Scientific Reports|June 11, 2014
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidasesNingning Liu, Chunjiao Liu, Xiaofen Li, et al.
Oncotarget|July 1, 2014
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growthNingning Liu, Xiaofen Li, Hongbiao Huang, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Scientific Reports|February 23, 2016
A microRNA-mediated decrease in eukaryotic initiation factor 2α promotes cell survival during PS-341 treatmentLili Jiang, Dan Zang, Songgang Yi, et al.
Scientific Reports|June 11, 2014
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidasesNingning Liu, Chunjiao Liu, Xiaofen Li, et al.
Oncotarget|July 1, 2014
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growthNingning Liu, Xiaofen Li, Hongbiao Huang, et al.
Pageof 1